Shandong Weigao Blood Purification Products Co (SHSE:603014) EBIT: ¥582 Mil (TTM As of Mar. 2026)


SHSE:603014 Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
38 GF Score
Price ¥36.00
! 2 Warning Signs
View Full Analysis

What is Shandong Weigao Blood Purification Products Co EBIT?

Shandong Weigao Blood Purification Products Co SHSE:603014 +9.99% 38 EBIT is ¥582 Mil as of Mar. 2026. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Shandong Weigao Blood Purification Products Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥140 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥582 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Weigao Blood Purification Products Co's annualized ROC % for the quarter that ended in Mar. 2026 was 9.90%. Shandong Weigao Blood Purification Products Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Weigao Blood Purification Products Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.34%.

Shandong Weigao Blood Purification Products Co  (SHSE:603014) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Weigao Blood Purification Products Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=570.496 * ( 1 - 15.43% )/( (4811.397 + 4937.427)/ 2 )
=482.4684672/4874.412
=9.90 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8608.491 - 992.047 - ( 2805.047 - max(0, 1415.381 - 4673.764+2805.047))
=4811.397

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8595.761 - 876.228 - ( 2782.106 - max(0, 1259.143 - 4667.307+2782.106))
=4937.427

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Weigao Blood Purification Products Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=560.996/( ( (3297.961 + max(378.737, 0)) + (3281.016 + max(585.609, 0)) )/ 2 )
=560.996/( ( 3676.698 + 3866.625 )/ 2 )
=560.996/3771.6615
=14.87 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(862.494 + 823.249 + 105.479) - (992.047 + 0 + 420.438)
=378.737

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(899.122 + 815.122 + 124.487) - (876.228 + 0 + 376.894)
=585.609

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Weigao Blood Purification Products Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=582.469/10907.890
=5.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co EBIT Related Terms

Shandong Weigao Blood Purification Products Co EBIT Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Blood Purification Products Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co EBIT Chart

Shandong Weigao Blood Purification Products Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 414.46 420.83 525.50 546.28 576.57

Shandong Weigao Blood Purification Products Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.35 130.05 142.29 169.88 140.25

SHSE:603014 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Weigao Blood Purification Products Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Blood Purification Products Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Blood Purification Products Co's EV-to-EBIT falls into.


SHSE:603014
38GF Score
Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Weigao Blood Purification Products Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥582 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥582 Mil mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a EBIT of ¥582 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Weigao Blood Purification Products Co.
Is Shandong Weigao Blood Purification Products Co's EBIT too high?
Shandong Weigao Blood Purification Products Co's current EBIT is ¥582 Mil. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's EBIT compare to ABT and SYK?
Shandong Weigao Blood Purification Products Co's EBIT of ¥582 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Weigao Blood Purification Products Co. Shandong Weigao Blood Purification Products Co's current EBIT is ¥582 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current EBIT of ¥582 Mil. The current EBIT is ¥582 Mil. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current EBIT is ¥582 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shandong Weigao Blood Purification Products Co Business Description

Address No. 7, Weigao West Road, Torch High-tech Industrial Development Zone, Shandong Province, Weihai, CHN, 264200
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
38GF Score

Get the complete analysis for SHSE:603014

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.00
Price